Microbiota
Conditions
Keywords
skin microbiota, 16S rRNA gene, hand foot sysdom, breast cancer chemotherapy
Brief summary
To skin microecology and breast cancer chemotherapy drug therapy as the breakthrough point, disease prevention and treatment of breast cancer in China, the important scientific problems in basic research, through in-depth study of skin micro ecological changes in advanced breast cancer chemotherapy and its regulatory mechanism, clear skin flora occurred after application of capecitabine and the influence and mechanism of the immune response;Finding markers for the treatment and prognosis of related diseases;Identify and isolate key strains and/or metabolites, and conduct intervention studies to reveal new mechanisms of skin microflora homeostasis and toxic and side effects of breast cancer chemotherapy.
Detailed description
To skin microecology and breast cancer chemotherapy drug therapy as the breakthrough point, disease prevention and treatment of breast cancer in China, the important scientific problems in basic research, through in-depth study of skin micro ecological changes in advanced breast cancer chemotherapy and its regulatory mechanism, clear skin flora occurred after application of capecitabine and the influence and mechanism of the immune response;Finding markers for the treatment and prognosis of related diseases;Identify and isolate key strains and/or metabolites, and conduct intervention studies to reveal new mechanisms of skin microflora homeostasis and toxic and side effects of breast cancer chemotherapy
Interventions
DRUGCapecitabine 150Mg Oral Tablet
Advanced breast cancer patients with first-line medication
Sponsors
Sponsor GmbH
First Affiliated Hospital of Harbin Medical University
Study design
Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* age: 18-65 years old * advanced breast cancer patients * healthy volunteers
Exclusion criteria
* previous skin disease history, or other skin disease activity at present * various antibiotics, prebiotics, probiotics or lactic acid products used within three months; * having a history of alcoholism for more than 2 years and smoking for years; * pregnancy or lactation; * have oral, respiratory and gastrointestinal diseases; * other metabolic diseases, such as obesity, hypertension, diabetes, stones, and liver diseases; * other autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, inflammatory bowel disease; * history of gastrointestinal surgery; * family genetic history, history of mental illness, etc.; * the subject is participating in other research projects; * other reasons are not considered suitable for continued clinical trials.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Transcriptional changes in skin microbiota | baseline,1 day, 21 days,42 days,65 days,85 days,106 days,127 days | The microbiota measured by 16S rRNA gene |
Countries
China
Contacts
Primary ContactYunwei Wei, doctor
Backup Contactxin Wu
Outcome results
None listed